Yi Tan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yi Tan has a total of 236 co-authors. Here are the top co-authors by number of shared publications:
Lu Cai
15 shared publicationsXiaoqing Yan
Chinese‐American Research Institute for Diabetic Complications,School of Pharmaceutical Sciences,Wenzhou Medical University,Wenzhou,China
13 shared publications- Lu Cai
Pediatric Research Institute, Department of Pediatrics, University of Louisville, Louisville, KY 40202, USA
11 shared publications Kupper A. Wintergerst
Wendy Novak Diabetes Institute, Norton Children's Hospital, Louisville, KY, USA; Norton Children's Endocrinology, Department of Pediatrics, University of Louisville, Norton Children's Hospital, Louisville, KY, USA; The Center for Integrative Environmental Health Sciences, University of Louisville School of Medicine, Louisville, KY, USA
10 shared publicationsXiaozhen Dai
School of Biosciences and Technology, Chengdu Medical College, Chengdu, Sichuan, China; Pediatric Research Institute, Department of Pediatrics, University of Louisville School of Medicine, Louisville, KY, USA
10 shared publicationsJing Chen
Pediatric Research Institute, Department of Pediatrics, University of Louisville School of Medicine, Louisville, KY, USA
7 shared publications
Latest Publications
- Open Access
- 24 October 2026
- Published by Springer Nature in Nature Communications
Gut epithelial aryl hydrocarbon receptor deficiency aggravates fungal dysbiosis-mediated neutrophilic allergic airway disease in mice
- 24 October 2026
- Published by Springer Nature in Nature Communications
Open AccessGut epithelial aryl hydrocarbon receptor deficiency aggravates fungal dysbiosis-mediated neutrophilic allergic airway disease in mice
- Open Access
- 1 April 2026
- Published by BMJ in eGastroenterology
- Vol. 4 (2) , e100417
Intestinal neutral ceramidase exacerbates MASH pathogenesis
Background: Metabolic dysfunction-associated steatotic liver disease and its more severe manifestation, metabolic dysfunction-associated steatohepatitis (MASH), are intimately linked to genetic factors, gut microbiota and barrier alteration. Ceramidases and ceramides are associated with MASH, yet the role of intestinal neutral ceramidase in MASH development remains unclear. Methods: Murine models with intestinal epithelial cell (IEC)-specific depletion of neutral ceramidase ( Asah2 ΔIEC ) or aryl hydrocarbon receptor ( AhR ΔIEC ) were subjected to either a Western diet (WD) at 6 weeks old for 10–12 months to induce MASH, or a hydrogenated vegetable oil, sucrose, palmitate and cholesterol (HSPC) diet to accelerate MASH progression. Fecal microbiota transplantation was performed in germ-free mice. Results: MASH is associated with the induction of neutral ceramidase, which reshapes the intestinal microbiota and metabolite profiles, leading to increased production of 2-hydroxyhippuric acid (2-HHA). We identified 2-HHA as an inhibitor of AhR signalling, a pathway that normally promotes intestinal fucosylation. Elevated 2-HHA suppresses AhR activity, reduces fucosylation and contributes to MASH and associated airway inflammation in mice fed WD or HSPC diet. Notably, IEC-specific deletion of neutral ceramidase decreases 2-HHA levels, restores AhR signalling, enhances fucosylation and protects against MASH. Consistently, intestinal AhR deficiency exacerbates MASH by reducing intestinal fucosylation, whereas supplementation with fucoidan increases fucosylation, improves barrier function and attenuates MASH. Conclusions: These findings identify intestinal neutral ceramidase as a key driver of MASH through a microbiota–2-HHA–AhR axis that impairs intestinal fucosylation and barrier function, highlighting a potential therapeutic target.
- 1 April 2026
- Published by BMJ in eGastroenterology
- Vol. 4 (2) , e100417
Open AccessIntestinal neutral ceramidase exacerbates MASH pathogenesis
Background: Metabolic dysfunction-associated steatotic liver disease and its more severe manifestation, metabolic dysfunction-associated steatohepatitis (MASH), are intimately linked to genetic factors, gut microbiota and barrier alteration. Ceramidases and ceramides are associated with MASH, yet the role of intestinal neutral ceramidase in MASH development remains unclear. Methods: Murine models with intestinal epithelial cell (IEC)-specific depletion of neutral ceramidase ( Asah2 ΔIEC ) or aryl hydrocarbon receptor ( AhR ΔIEC ) were subjected to either a Western diet (WD) at 6 weeks old for 10–12 months to induce MASH, or a hydrogenated vegetable oil, sucrose, palmitate and cholesterol (HSPC) diet to accelerate MASH progression. Fecal microbiota transplantation was performed in germ-free mice. Results: MASH is associated with the induction of neutral ceramidase, which reshapes the intestinal microbiota and metabolite profiles, leading to increased production of 2-hydroxyhippuric acid (2-HHA). We identified 2-HHA as an inhibitor of AhR signalling, a pathway that normally promotes intestinal fucosylation. Elevated 2-HHA suppresses AhR activity, reduces fucosylation and contributes to MASH and associated airway inflammation in mice fed WD or HSPC diet. Notably, IEC-specific deletion of neutral ceramidase decreases 2-HHA levels, restores AhR signalling, enhances fucosylation and protects against MASH. Consistently, intestinal AhR deficiency exacerbates MASH by reducing intestinal fucosylation, whereas supplementation with fucoidan increases fucosylation, improves barrier function and attenuates MASH. Conclusions: These findings identify intestinal neutral ceramidase as a key driver of MASH through a microbiota–2-HHA–AhR axis that impairs intestinal fucosylation and barrier function, highlighting a potential therapeutic target.
- Open Access
Human FGF1ΔHBS Gene Therapy as Treatment for Metabolic Dysfunction-Associated Steatohepatitis in ApoE-KO Mice
The prevalence of metabolic dysfunction-associated steatohepatitis (MASH) is rising worldwide. hFGF1ΔHBS, a variant of human fibroblast growth factor 1 with three substitutions in its heparin-binding sites, was previously shown by our group to ameliorate fatty liver. However, hFGF1ΔHBS also significantly modulates systemic metabolism, making it unclear whether its hepatic benefits arise from direct liver-specific actions. Additionally, its poor pharmacokinetic profile underscores the need for alternative delivery strategies. Here, we employed adeno-associated virus serotype 8 under the thyroxine-binding globulin promoter (AAV8-TBG) to achieve sustained, hepatocyte-specific expression of hFGF1ΔHBS. In high-fat-, high-cholesterol-diet-fed apolipoprotein E knockout mice, liver-directed hFGF1ΔHBS expression markedly reduced hepatic steatosis, inflammation, and fibrosis, independent of changes in body weight, blood glucose, insulin sensitivity, body composition, or circulating triglyceride and cholesterol levels. Mechanistically, hFGF1ΔHBS gene transfer normalized fatty acid synthesis and suppressed fatty acid uptake by downregulation of stearoyl-CoA desaturase-1 and cluster of differentiation 36. Importantly, these therapeutic effects were achieved without inducing hepatic hyperproliferation, as evidenced by unchanged expression of proliferating cell nuclear antigen and antigen Kiel 67. Collectively, our findings demonstrate that hFGF1ΔHBS exerts direct hepatoprotective effects and that AAV8-TBG-mediated liver-directed hFGF1ΔHBS delivery represents a safe and effective strategy for treating MASH.
Open AccessHuman FGF1ΔHBS Gene Therapy as Treatment for Metabolic Dysfunction-Associated Steatohepatitis in ApoE-KO Mice
The prevalence of metabolic dysfunction-associated steatohepatitis (MASH) is rising worldwide. hFGF1ΔHBS, a variant of human fibroblast growth factor 1 with three substitutions in its heparin-binding sites, was previously shown by our group to ameliorate fatty liver. However, hFGF1ΔHBS also significantly modulates systemic metabolism, making it unclear whether its hepatic benefits arise from direct liver-specific actions. Additionally, its poor pharmacokinetic profile underscores the need for alternative delivery strategies. Here, we employed adeno-associated virus serotype 8 under the thyroxine-binding globulin promoter (AAV8-TBG) to achieve sustained, hepatocyte-specific expression of hFGF1ΔHBS. In high-fat-, high-cholesterol-diet-fed apolipoprotein E knockout mice, liver-directed hFGF1ΔHBS expression markedly reduced hepatic steatosis, inflammation, and fibrosis, independent of changes in body weight, blood glucose, insulin sensitivity, body composition, or circulating triglyceride and cholesterol levels. Mechanistically, hFGF1ΔHBS gene transfer normalized fatty acid synthesis and suppressed fatty acid uptake by downregulation of stearoyl-CoA desaturase-1 and cluster of differentiation 36. Importantly, these therapeutic effects were achieved without inducing hepatic hyperproliferation, as evidenced by unchanged expression of proliferating cell nuclear antigen and antigen Kiel 67. Collectively, our findings demonstrate that hFGF1ΔHBS exerts direct hepatoprotective effects and that AAV8-TBG-mediated liver-directed hFGF1ΔHBS delivery represents a safe and effective strategy for treating MASH.
- Open Access
- 15 July 2025
- Published by Elsevier in Pharmacological Research
- Vol. 218, 107858
Fibroblast growth factor 16: Molecular mechanisms, signalling crosstalk, and emerging roles in cardiac biology and metabolic regulation
- 15 July 2025
- Published by Elsevier in Pharmacological Research
- Vol. 218, 107858
Open AccessFibroblast growth factor 16: Molecular mechanisms, signalling crosstalk, and emerging roles in cardiac biology and metabolic regulation
- Open Access
- 29 May 2025
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 9 (8) , bvaf096
High-Fat Diet Differentially Regulates Fibroblast Growth Factor Expression in Metabolic Tissues of Young and Aged Male Mice
Context: Fibroblast growth factors (FGFs) play critical roles in metabolism, yet their tissue-specific expression in response to obesity and aging remains unclear. Objective: We investigated the mRNA expression profiles of FGFs along with their receptors, across major metabolic tissues—heart, liver, kidney, skeletal muscle, gonadal white adipose tissue, subcutaneous white adipose tissue, and brown adipose tissue. Methods: Young (7-week-old) and aged (12-month-old) male mice were fed either a high-fat diet (HFD) or a normal diet for 11 weeks. Real-time quantitative polymerase chain reaction was used to measure mRNA expression levels of FGFs and their receptors. Results: The FGF system exhibited widespread expression, with the heart showing the most pronounced response to HFD-induced stress, followed by the liver and kidney, while skeletal muscle exhibited minimal changes. Adipose tissues displayed distinct FGF expression patterns under HFD conditions, with FGF1 being the most responsive, followed by FGF9. Although aged mice exhibited significantly greater body and organ weights, FGF expression profiles showed minimal variation between young and aged mice in most organs except heart. Conclusion: These findings underscore the tissue-specific dynamics of the FGF system under metabolic stress, identifying FGF1 as a promising therapeutic target for addressing obesity- and aging-related metabolic dysfunction.
- 29 May 2025
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 9 (8) , bvaf096
Open AccessHigh-Fat Diet Differentially Regulates Fibroblast Growth Factor Expression in Metabolic Tissues of Young and Aged Male Mice
Context: Fibroblast growth factors (FGFs) play critical roles in metabolism, yet their tissue-specific expression in response to obesity and aging remains unclear. Objective: We investigated the mRNA expression profiles of FGFs along with their receptors, across major metabolic tissues—heart, liver, kidney, skeletal muscle, gonadal white adipose tissue, subcutaneous white adipose tissue, and brown adipose tissue. Methods: Young (7-week-old) and aged (12-month-old) male mice were fed either a high-fat diet (HFD) or a normal diet for 11 weeks. Real-time quantitative polymerase chain reaction was used to measure mRNA expression levels of FGFs and their receptors. Results: The FGF system exhibited widespread expression, with the heart showing the most pronounced response to HFD-induced stress, followed by the liver and kidney, while skeletal muscle exhibited minimal changes. Adipose tissues displayed distinct FGF expression patterns under HFD conditions, with FGF1 being the most responsive, followed by FGF9. Although aged mice exhibited significantly greater body and organ weights, FGF expression profiles showed minimal variation between young and aged mice in most organs except heart. Conclusion: These findings underscore the tissue-specific dynamics of the FGF system under metabolic stress, identifying FGF1 as a promising therapeutic target for addressing obesity- and aging-related metabolic dysfunction.
- Open Access
Withaferin A as a Potential Therapeutic Target for the Treatment of Angiotensin II-Induced Cardiac Cachexia
In our previous studies, we showed that the generation of ovarian tumors in NSG mice (immune-compromised) resulted in the induction of muscle and cardiac cachexia, and treatment with withaferin A (WFA; a steroidal lactone) attenuated both muscle and cardiac cachexia. However, our studies could not address if these restorations by WFA were mediated by its anti-tumorigenic properties that might, in turn, reduce the tumor burden or WFA’s direct, inherent anti-cachectic properties. To address this important issue, in our present study, we used a cachectic model induced by the continuous infusion of Ang II by implanting osmotic pumps in immunocompetent C57BL/6 mice. The continuous infusion of Ang II resulted in the loss of the normal functions of the left ventricle (LV) (both systolic and diastolic), including a significant reduction in fractional shortening, an increase in heart weight and LV wall thickness, and the development of cardiac hypertrophy. The infusion of Ang II also resulted in the development of cardiac fibrosis, and significant increases in the expression levels of genes (ANP, BNP, and MHCβ) associated with cardiac hypertrophy and the chemical staining of the collagen abundance as an indication of fibrosis. In addition, Ang II caused a significant increase in expression levels of inflammatory cytokines (IL-6, IL-17, MIP-2, and IFNγ), NLRP3 inflammasomes, AT1 receptor, and a decrease in AT2 receptor. Treatment with WFA rescued the LV functions and heart hypertrophy and fibrosis. Our results demonstrated, for the first time, that, while WFA has anti-tumorigenic properties, it also ameliorates the cardiac dysfunction induced by Ang II, suggesting that it could be an anticachectic agent that induces direct effects on cardiac muscles.
Open AccessWithaferin A as a Potential Therapeutic Target for the Treatment of Angiotensin II-Induced Cardiac Cachexia
In our previous studies, we showed that the generation of ovarian tumors in NSG mice (immune-compromised) resulted in the induction of muscle and cardiac cachexia, and treatment with withaferin A (WFA; a steroidal lactone) attenuated both muscle and cardiac cachexia. However, our studies could not address if these restorations by WFA were mediated by its anti-tumorigenic properties that might, in turn, reduce the tumor burden or WFA’s direct, inherent anti-cachectic properties. To address this important issue, in our present study, we used a cachectic model induced by the continuous infusion of Ang II by implanting osmotic pumps in immunocompetent C57BL/6 mice. The continuous infusion of Ang II resulted in the loss of the normal functions of the left ventricle (LV) (both systolic and diastolic), including a significant reduction in fractional shortening, an increase in heart weight and LV wall thickness, and the development of cardiac hypertrophy. The infusion of Ang II also resulted in the development of cardiac fibrosis, and significant increases in the expression levels of genes (ANP, BNP, and MHCβ) associated with cardiac hypertrophy and the chemical staining of the collagen abundance as an indication of fibrosis. In addition, Ang II caused a significant increase in expression levels of inflammatory cytokines (IL-6, IL-17, MIP-2, and IFNγ), NLRP3 inflammasomes, AT1 receptor, and a decrease in AT2 receptor. Treatment with WFA rescued the LV functions and heart hypertrophy and fibrosis. Our results demonstrated, for the first time, that, while WFA has anti-tumorigenic properties, it also ameliorates the cardiac dysfunction induced by Ang II, suggesting that it could be an anticachectic agent that induces direct effects on cardiac muscles.
- Open Access
- 1 February 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-20
Neutral ceramidase regulates breast cancer progression by metabolic programming of TREM2-associated macrophages
The tumor microenvironment is reprogrammed by cancer cells and participates in all stages of tumor progression. Neutral ceramidase is a key regulator of ceramide, the central intermediate in sphingolipid metabolism. The contribution of neutral ceramidase to the reprogramming of the tumor microenvironment is not well understood. Here, we find that deletion of neutral ceramidase in multiple breast cancer models in female mice accelerates tumor growth. Our result show that Ly6C+CD39+ tumor-infiltrating CD8 T cells are enriched in the tumor microenvironment and display an exhausted phenotype. Deletion of myeloid neutral ceramidase in vivo and in vitro induces exhaustion in tumor-infiltrating Ly6C+CD39+CD8+ T cells. Mechanistically, myeloid neutral ceramidase is required for the generation of lipid droplets and for the induction of lipolysis, which generate fatty acids for fatty-acid oxidation and orchestrate macrophage metabolism. Metabolite ceramide leads to reprogramming of macrophages toward immune suppressive TREM2+ tumor associated macrophages, which promote CD8 T cells exhaustion.
- 1 February 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-20
Open AccessNeutral ceramidase regulates breast cancer progression by metabolic programming of TREM2-associated macrophages
The tumor microenvironment is reprogrammed by cancer cells and participates in all stages of tumor progression. Neutral ceramidase is a key regulator of ceramide, the central intermediate in sphingolipid metabolism. The contribution of neutral ceramidase to the reprogramming of the tumor microenvironment is not well understood. Here, we find that deletion of neutral ceramidase in multiple breast cancer models in female mice accelerates tumor growth. Our result show that Ly6C+CD39+ tumor-infiltrating CD8 T cells are enriched in the tumor microenvironment and display an exhausted phenotype. Deletion of myeloid neutral ceramidase in vivo and in vitro induces exhaustion in tumor-infiltrating Ly6C+CD39+CD8+ T cells. Mechanistically, myeloid neutral ceramidase is required for the generation of lipid droplets and for the induction of lipolysis, which generate fatty acids for fatty-acid oxidation and orchestrate macrophage metabolism. Metabolite ceramide leads to reprogramming of macrophages toward immune suppressive TREM2+ tumor associated macrophages, which promote CD8 T cells exhaustion.
- 21 September 2023
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 477, 116694
Diabetic cardiomyopathy – Zinc preventive and therapeutic potentials by its anti-oxidative stress and sensitizing insulin signaling pathways
- 21 September 2023
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 477, 116694
Diabetic cardiomyopathy – Zinc preventive and therapeutic potentials by its anti-oxidative stress and sensitizing insulin signaling pathways
- Open Access
- 3 August 2023
- Published by Wiley in Aging Cell
- Vol. 22 (9) , e13930
Alterations of SIRT1/SIRT3 subcellular distribution in aging undermine cardiometabolic homeostasis during ischemia and reperfusion
Age‐related sensors Sirtuin1 (SIRT1) and Sirtuin3 (SIRT3) play an essential role in the protective response upon myocardial ischemia and/or reperfusion (I/R). However, the subcellular localization and co‐regulatory network between cardiac SIRT1 and SIRT3 remain unknown, especially their effects on age‐related metabolic regulation during acute ischemia and I/R. Here, we found that defects of cardiac SIRT1 or SIRT3 with aging result in an exacerbated cardiac physiological structural and functional deterioration after acute ischemic stress and failed recovery through reperfusion operation. In aged hearts, SIRT1 translocated into mitochondria and recruited more mitochondria SIRT3 to enhance their interaction during acute ischemia, acting as adaptive protection for the aging hearts from further mitochondria dysfunction. Subsequently, SIRT3‐targeted proteomics revealed that SIRT1 plays a crucial role in maintaining mitochondrial integrity through SIRT3‐mediated substrate metabolism during acute ischemic and I/R stress. Although the loss of SIRT1/SIRT3 led to a compromised PGC‐1α/PPARα‐mediated transcriptional control of fatty acid oxidation in response to acute ischemia and I/R, their crosstalk in mitochondria plays a more important role in the aging heart during acute ischemia. However, the increased mitochondria SIRT1‐SIRT3 interaction promoted adaptive protection to aging‐related fatty acid metabolic disorder via deacetylation of long‐chain acyl CoA dehydrogenase (LCAD) during ischemic insults. Therefore, the dynamic network of SIRT1/SIRT3 acts as a mediator that regulates adaptive metabolic response to improve the tolerance of aged hearts to ischemic insults, which will facilitate investigation into the role of SIRT1/SIRT3 in age‐related ischemic heart disease.
- 3 August 2023
- Published by Wiley in Aging Cell
- Vol. 22 (9) , e13930
Open AccessAlterations of SIRT1/SIRT3 subcellular distribution in aging undermine cardiometabolic homeostasis during ischemia and reperfusion
Age‐related sensors Sirtuin1 (SIRT1) and Sirtuin3 (SIRT3) play an essential role in the protective response upon myocardial ischemia and/or reperfusion (I/R). However, the subcellular localization and co‐regulatory network between cardiac SIRT1 and SIRT3 remain unknown, especially their effects on age‐related metabolic regulation during acute ischemia and I/R. Here, we found that defects of cardiac SIRT1 or SIRT3 with aging result in an exacerbated cardiac physiological structural and functional deterioration after acute ischemic stress and failed recovery through reperfusion operation. In aged hearts, SIRT1 translocated into mitochondria and recruited more mitochondria SIRT3 to enhance their interaction during acute ischemia, acting as adaptive protection for the aging hearts from further mitochondria dysfunction. Subsequently, SIRT3‐targeted proteomics revealed that SIRT1 plays a crucial role in maintaining mitochondrial integrity through SIRT3‐mediated substrate metabolism during acute ischemic and I/R stress. Although the loss of SIRT1/SIRT3 led to a compromised PGC‐1α/PPARα‐mediated transcriptional control of fatty acid oxidation in response to acute ischemia and I/R, their crosstalk in mitochondria plays a more important role in the aging heart during acute ischemia. However, the increased mitochondria SIRT1‐SIRT3 interaction promoted adaptive protection to aging‐related fatty acid metabolic disorder via deacetylation of long‐chain acyl CoA dehydrogenase (LCAD) during ischemic insults. Therefore, the dynamic network of SIRT1/SIRT3 acts as a mediator that regulates adaptive metabolic response to improve the tolerance of aged hearts to ischemic insults, which will facilitate investigation into the role of SIRT1/SIRT3 in age‐related ischemic heart disease.
- Open Access
- 28 August 2022
- Published by Elsevier in Redox Biology
- Vol. 56, 102449
Nrf2 transcriptional upregulation of IDH2 to tune mitochondrial dynamics and rescue angiogenic function of diabetic EPCs
- 28 August 2022
- Published by Elsevier in Redox Biology
- Vol. 56, 102449
Open AccessNrf2 transcriptional upregulation of IDH2 to tune mitochondrial dynamics and rescue angiogenic function of diabetic EPCs